An Investigational New Drug application for the Nectin4/TROP2 ADC is planned for submission to the U.S. Food and Drug Administration in ... played an integral role in its acquisition by Bristol Myers ...

Ms. Nassif brings an extensive track record of successfully developing commercial strategies for multiple FDA-approved drugsAppointment initiates ...

TORONTO and PHILADELPHIA, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd (NASDAQ: MDCX TSXV: MDCX) (the “Company”) is pleased to announce the appointment of Faisal Mehmud, MD as Chief Medical ...

The decision in Europe follows an approval granted by the US Food and Drug Administration (FDA) in March this year.

which Bristol Myers Squibb acquired in March 2024. At Karuna, he served as Senior Vice President of Regulatory Affairs and ...

On September 16, 2024, Immatics announced the proof-of-concept clinical data for the first candidate of its next-generation, ...

Bristol Myers Squibb gets positive CHMP opinion for Opdivo plus Yervoy to treat adult with MSI-H or dMMR metastatic colorectal cancer: Princeton, New Jersey Monday, November 18, 2 ...

The EMA's CHMP has recommended approval of a combination therapy of BMS's Opdivo and Yervoy for the treatment of colorectal ...

Dramatic study results point to the potential for a steroid-sparing option for patients with the underrecognized multiorgan ...

EMA committee recommends approval of Bristol Myers’ repotrectinib to treat advanced ROS1-positive NSCLC & NTRK-positive solid tumours: Princeton, New Jersey Monday, November 18, ...

Most recently, Dr. Palmer served as Senior Vice President of Global Medical Affairs, Immunology and Neuroscience at Bristol Myers Squibb ... Track Designation and Orphan Drug Designation from the U.S.

Health stocks tumbled as vaccine sceptic RFK Jr. was named by President-elect Trump to head the Department of Health and ...